53101-05-6

Basic information

• Product Name: Ethyl 4-(3-Nitrophenyl)thiazole-2-carboxylate
• Synonyms: Ethyl 4-(3-Nitrophenyl)thiazole-2-carboxylate
• CAS NO: 53101-05-6
• Molecular Formula: C₁₂H₁₀N₂O₄S
• Molecular Weight: 278.2838
• Mol File: 53101-05-6.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Ethyl 4-(3-Nitrophenyl)thiazole-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 4-(3-Nitrophenyl)thiazole-2-carboxylate(53101-05-6)
• EPA Substance Registry System: Ethyl 4-(3-Nitrophenyl)thiazole-2-carboxylate(53101-05-6)

Safety Data

• Hazardous Substances Data: 53101-05-6(Hazardous Substances Data)

Upstream product

• 121-89-1 3-Nitroacetophenone 
• 16982-21-1 ethyl 2-amino-2-thioxoacetate 
• 2227-64-7 3'-nitro-2-bromoacetophenone 

Downstream Products

• 460750-29-2 4-(3-aminophenyl)thiazole-2-carboxylic acid amide 
• 942232-14-6 C₃₄H₃₉N₅O₅S 
• 528884-39-1 4-(3-(2-(5-cyclohexyl-1-(3,3-dimethyl-2-oxo-butyl)-2-oxo-1,2-dihydro-3H-1,3,4-benzotriazepin-3-yl)-acetylamino)-phenyl)-thiazole-2-carboxylic acid 
• 950603-76-6 C₃₄H₄₈ClN₃O₅SSi 
• 460750-28-1 4-(3-amino-phenyl)-thiazole-2-carboxylic acid ethyl ester 

Relevant articles and documents

SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS

Disclosed are compounds of Formula (I): or a stereoisomer, a tautomer, or a salt or solvate thereof, wherein Q is C2-6 alkenyl or C2-6 alkynyl, each substituted with zero to 2 R1; and the other variables are as defined herein. These compounds modulate the activity of farnesoid X receptor (FXR), for example, as agonists. Also disclosed are pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with FXR dysregulation, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.

Design, synthesis, and biological evaluation of N,N-disubstituted-4-arylthiazole-2-methylamine derivatives as cholesteryl ester transfer inhibitors

Cholesteryl ester transfer protein (CETP) has been identified as a potential target for cardiovascular disease (CVD) for its important role in the reverse cholesteryl transfer (RCT) process. In our previous work, compound 5 was discovered as a moderate CETP inhibitor. The replacement of the amide linker by heterocyclic aromatics and then a series of N,N-substituted-4-arylthiazole-2-methylamine derivatives were designed by utilizing a conformational restriction strategy. Thirty-six compounds were synthesized and evaluated for their CETP inhibitory activities. Structure-activity relationship studies indicate that electron donor groups substituted ring A, and electron-withdrawing groups at the 4-position of ring B were critical for potency. Among these compounds, compound 30 exhibited excellent CETP inhibitory activity (IC50 = 0.79 ± 0.02 μM) in vitro and showed an acceptable metabolic stability.

Fructose 1,6-bisphosphatase inhibitors

The present invention relates to certain quinazoline compounds which have utility in the treatment of diabetes mellitus, hypercholesterolemia, hyperlipidemia, diabetic complications and cancer. The invention also relates to pharmaceutical compositions and